Wedge Industrial (000534) Q1 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 2026 earnings summary
9 Jul, 2026Executive summary
Revenue for Q1 2026 reached ¥359.78 million, up 7.39% year-over-year.
Net profit attributable to shareholders was ¥77.47 million, a 6.58% increase year-over-year.
Cash flow from operating activities was negative at -¥26.81 million, declining further from last year.
Total assets grew 17.25% to ¥5.38 billion compared to year-end 2025.
Financial highlights
Operating income rose to ¥359.78 million from ¥335.04 million year-over-year.
Net profit excluding non-recurring items was ¥71.87 million, up 4.02% year-over-year.
Basic EPS increased to ¥0.1534 from ¥0.1457 year-over-year.
Weighted average ROE was 4.70%, down 0.40 percentage points from year-end 2025.
Non-recurring gains included government subsidies and other income totaling ¥10.99 million.
Outlook and guidance
Strategic investors were introduced to a key subsidiary, with significant capital injection and share transfer completed in March 2026.
Latest events from Wedge Industrial
- Net profit rose 12.49% YoY on higher revenue and robust pharmaceutical segment growth.000534
Q2 20249 Jul 2026 - Q3 2024 saw double-digit profit growth, robust cash flow, and major investments in expansion.000534
Q3 20249 Jul 2026 - Audit confirms accurate related party fund flows and significant intra-group transactions in 2024.000534
Q4 20249 Jul 2026 - Revenue and profit surged, with robust growth in pharma and alloy businesses and strategic investments.000534
Q2 20259 Jul 2026 - Revenue and net profit rose over 10% year-over-year, with robust growth in high-temperature alloys.000534
Q1 20259 Jul 2026 - Revenue and profit surged over 20% year-over-year, led by high-temperature alloy sales.000534
Q3 20259 Jul 2026 - Revenue up 19.62% to ¥1.29B, net profit up 2.22%, with strong R&D and no cash dividend.000534
Q4 20259 Jul 2026